Intrinsic value of Aralez Pharmaceuticals - ARLZ

Previous Close

$0.04

  Intrinsic Value

$0.91

stock screener

  Rating & Target

str. buy

+999%

Previous close

$0.04

 
Intrinsic value

$0.91

 
Up/down potential

+999%

 
Rating

str. buy

We calculate the intrinsic value of ARLZ stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2017), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.0

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046
   2047

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  170
  262
  392
  569
  802
  1,103
  1,480
  1,944
  2,501
  3,159
  3,923
  4,796
  5,781
  6,878
  8,088
  9,408
  10,837
  12,373
  14,013
  15,755
  17,596
  19,534
  21,569
  23,699
  25,924
  28,244
  30,659
  33,173
  35,786
  38,503
Variable operating expenses, $m
  74
  93
  120
  156
  205
  267
  344
  440
  555
  691
  809
  989
  1,192
  1,418
  1,668
  1,940
  2,234
  2,551
  2,889
  3,248
  3,628
  4,028
  4,447
  4,886
  5,345
  5,824
  6,322
  6,840
  7,379
  7,939
Fixed operating expenses, $m
  131
  134
  137
  140
  143
  146
  149
  152
  156
  159
  163
  166
  170
  174
  177
  181
  185
  189
  194
  198
  202
  207
  211
  216
  221
  225
  230
  235
  241
  246
Total operating expenses, $m
  205
  227
  257
  296
  348
  413
  493
  592
  711
  850
  972
  1,155
  1,362
  1,592
  1,845
  2,121
  2,419
  2,740
  3,083
  3,446
  3,830
  4,235
  4,658
  5,102
  5,566
  6,049
  6,552
  7,075
  7,620
  8,185
Operating income, $m
  -35
  35
  135
  273
  455
  690
  987
  1,351
  1,791
  2,309
  2,951
  3,641
  4,419
  5,286
  6,243
  7,287
  8,417
  9,632
  10,930
  12,308
  13,766
  15,300
  16,911
  18,597
  20,358
  22,195
  24,107
  26,098
  28,167
  30,318
EBITDA, $m
  70
  176
  327
  533
  806
  1,158
  1,602
  2,146
  2,802
  3,577
  4,477
  5,506
  6,667
  7,961
  9,387
  10,944
  12,631
  14,443
  16,378
  18,434
  20,607
  22,895
  25,297
  27,811
  30,437
  33,176
  36,028
  38,995
  42,081
  45,288
Interest expense (income), $m
  0
  27
  48
  83
  132
  198
  286
  400
  542
  717
  927
  1,175
  1,463
  1,792
  2,163
  2,576
  3,032
  3,530
  4,069
  4,648
  5,266
  5,922
  6,616
  7,347
  8,114
  8,917
  9,755
  10,630
  11,540
  12,488
  13,473
Earnings before tax, $m
  -62
  -13
  53
  141
  257
  404
  587
  810
  1,074
  1,383
  1,777
  2,178
  2,627
  3,123
  3,666
  4,254
  4,887
  5,564
  6,282
  7,043
  7,843
  8,684
  9,564
  10,483
  11,441
  12,439
  13,478
  14,557
  15,680
  16,845
Tax expense, $m
  0
  0
  14
  38
  69
  109
  159
  219
  290
  373
  480
  588
  709
  843
  990
  1,149
  1,320
  1,502
  1,696
  1,902
  2,118
  2,345
  2,582
  2,830
  3,089
  3,359
  3,639
  3,931
  4,233
  4,548
Net income, $m
  -62
  -13
  38
  103
  187
  295
  429
  591
  784
  1,009
  1,297
  1,590
  1,918
  2,280
  2,676
  3,106
  3,568
  4,061
  4,586
  5,141
  5,726
  6,339
  6,982
  7,653
  8,352
  9,081
  9,839
  10,627
  11,446
  12,297

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  725
  1,120
  1,675
  2,430
  3,428
  4,713
  6,326
  8,307
  10,689
  13,501
  16,765
  20,496
  24,705
  29,394
  34,562
  40,204
  46,312
  52,875
  59,884
  67,327
  75,196
  83,481
  92,176
  101,278
  110,785
  120,699
  131,023
  141,765
  152,934
  164,542
Adjusted assets (=assets-cash), $m
  725
  1,120
  1,675
  2,430
  3,428
  4,713
  6,326
  8,307
  10,689
  13,501
  16,765
  20,496
  24,705
  29,394
  34,562
  40,204
  46,312
  52,875
  59,884
  67,327
  75,196
  83,481
  92,176
  101,278
  110,785
  120,699
  131,023
  141,765
  152,934
  164,542
Revenue / Adjusted assets
  0.234
  0.234
  0.234
  0.234
  0.234
  0.234
  0.234
  0.234
  0.234
  0.234
  0.234
  0.234
  0.234
  0.234
  0.234
  0.234
  0.234
  0.234
  0.234
  0.234
  0.234
  0.234
  0.234
  0.234
  0.234
  0.234
  0.234
  0.234
  0.234
  0.234
Average production assets, $m
  659
  1,019
  1,524
  2,211
  3,119
  4,288
  5,755
  7,557
  9,724
  12,283
  15,252
  18,647
  22,476
  26,742
  31,444
  36,577
  42,134
  48,105
  54,482
  61,254
  68,412
  75,950
  83,861
  92,142
  100,792
  109,811
  119,204
  128,976
  139,138
  149,699
Working capital, $m
  -27
  -42
  -63
  -91
  -128
  -176
  -237
  -311
  -400
  -505
  -628
  -767
  -925
  -1,101
  -1,294
  -1,505
  -1,734
  -1,980
  -2,242
  -2,521
  -2,815
  -3,126
  -3,451
  -3,792
  -4,148
  -4,519
  -4,906
  -5,308
  -5,726
  -6,160
Total debt, $m
  488
  844
  1,343
  2,023
  2,921
  4,078
  5,530
  7,312
  9,456
  11,987
  14,924
  18,283
  22,071
  26,291
  30,942
  36,020
  41,517
  47,424
  53,732
  60,431
  67,512
  74,969
  82,795
  90,987
  99,543
  108,465
  117,757
  127,424
  137,476
  147,924
Total liabilities, $m
  652
  1,008
  1,507
  2,187
  3,085
  4,242
  5,693
  7,476
  9,620
  12,150
  15,088
  18,447
  22,234
  26,455
  31,106
  36,184
  41,681
  47,588
  53,896
  60,595
  67,676
  75,133
  82,959
  91,150
  99,707
  108,629
  117,921
  127,588
  137,640
  148,088
Total equity, $m
  72
  112
  167
  243
  343
  471
  633
  831
  1,069
  1,350
  1,676
  2,050
  2,470
  2,939
  3,456
  4,020
  4,631
  5,288
  5,988
  6,733
  7,520
  8,348
  9,218
  10,128
  11,079
  12,070
  13,102
  14,176
  15,293
  16,454
Total liabilities and equity, $m
  724
  1,120
  1,674
  2,430
  3,428
  4,713
  6,326
  8,307
  10,689
  13,500
  16,764
  20,497
  24,704
  29,394
  34,562
  40,204
  46,312
  52,876
  59,884
  67,328
  75,196
  83,481
  92,177
  101,278
  110,786
  120,699
  131,023
  141,764
  152,933
  164,542
Debt-to-equity ratio
  6.740
  7.540
  8.020
  8.330
  8.520
  8.650
  8.740
  8.800
  8.850
  8.880
  8.900
  8.920
  8.930
  8.940
  8.950
  8.960
  8.960
  8.970
  8.970
  8.980
  8.980
  8.980
  8.980
  8.980
  8.990
  8.990
  8.990
  8.990
  8.990
  8.990
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -62
  -13
  38
  103
  187
  295
  429
  591
  784
  1,009
  1,297
  1,590
  1,918
  2,280
  2,676
  3,106
  3,568
  4,061
  4,586
  5,141
  5,726
  6,339
  6,982
  7,653
  8,352
  9,081
  9,839
  10,627
  11,446
  12,297
Depreciation, amort., depletion, $m
  105
  141
  192
  260
  351
  468
  615
  795
  1,012
  1,267
  1,525
  1,865
  2,248
  2,674
  3,144
  3,658
  4,213
  4,811
  5,448
  6,125
  6,841
  7,595
  8,386
  9,214
  10,079
  10,981
  11,920
  12,898
  13,914
  14,970
Funds from operations, $m
  43
  128
  230
  363
  538
  763
  1,043
  1,386
  1,796
  2,277
  2,822
  3,455
  4,166
  4,954
  5,821
  6,763
  7,781
  8,872
  10,034
  11,267
  12,567
  13,934
  15,368
  16,867
  18,431
  20,062
  21,759
  23,525
  25,360
  27,267
Change in working capital, $m
  -10
  -15
  -21
  -28
  -37
  -48
  -60
  -74
  -89
  -105
  -122
  -140
  -158
  -176
  -193
  -211
  -229
  -246
  -262
  -279
  -295
  -310
  -326
  -341
  -356
  -371
  -387
  -402
  -418
  -435
Cash from operations, $m
  53
  143
  251
  391
  576
  811
  1,104
  1,460
  1,885
  2,382
  2,944
  3,595
  4,323
  5,130
  6,014
  6,975
  8,010
  9,118
  10,297
  11,545
  12,861
  14,244
  15,693
  17,208
  18,787
  20,433
  22,146
  23,927
  25,778
  27,702
Maintenance CAPEX, $m
  -41
  -66
  -102
  -152
  -221
  -312
  -429
  -576
  -756
  -972
  -1,228
  -1,525
  -1,865
  -2,248
  -2,674
  -3,144
  -3,658
  -4,213
  -4,811
  -5,448
  -6,125
  -6,841
  -7,595
  -8,386
  -9,214
  -10,079
  -10,981
  -11,920
  -12,898
  -13,914
New CAPEX, $m
  -248
  -359
  -505
  -687
  -908
  -1,169
  -1,468
  -1,802
  -2,167
  -2,558
  -2,970
  -3,395
  -3,829
  -4,266
  -4,702
  -5,133
  -5,557
  -5,971
  -6,376
  -6,772
  -7,159
  -7,538
  -7,911
  -8,281
  -8,650
  -9,019
  -9,393
  -9,773
  -10,161
  -10,561
Cash from investing activities, $m
  -289
  -425
  -607
  -839
  -1,129
  -1,481
  -1,897
  -2,378
  -2,923
  -3,530
  -4,198
  -4,920
  -5,694
  -6,514
  -7,376
  -8,277
  -9,215
  -10,184
  -11,187
  -12,220
  -13,284
  -14,379
  -15,506
  -16,667
  -17,864
  -19,098
  -20,374
  -21,693
  -23,059
  -24,475
Free cash flow, $m
  -236
  -282
  -356
  -448
  -554
  -670
  -793
  -917
  -1,038
  -1,149
  -1,253
  -1,326
  -1,370
  -1,384
  -1,362
  -1,303
  -1,205
  -1,067
  -890
  -675
  -422
  -134
  187
  540
  924
  1,335
  1,772
  2,234
  2,719
  3,227
Issuance/(repayment) of debt, $m
  214
  356
  499
  680
  898
  1,156
  1,452
  1,782
  2,144
  2,531
  2,938
  3,359
  3,788
  4,220
  4,651
  5,078
  5,497
  5,907
  6,308
  6,699
  7,082
  7,457
  7,826
  8,192
  8,556
  8,922
  9,292
  9,667
  10,052
  10,448
Issuance/(repurchase) of shares, $m
  120
  52
  17
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  334
  408
  516
  680
  898
  1,156
  1,452
  1,782
  2,144
  2,531
  2,938
  3,359
  3,788
  4,220
  4,651
  5,078
  5,497
  5,907
  6,308
  6,699
  7,082
  7,457
  7,826
  8,192
  8,556
  8,922
  9,292
  9,667
  10,052
  10,448
Total cash flow (excl. dividends), $m
  98
  126
  161
  232
  345
  487
  659
  865
  1,106
  1,382
  1,684
  2,033
  2,417
  2,836
  3,289
  3,775
  4,292
  4,840
  5,418
  6,024
  6,659
  7,322
  8,013
  8,732
  9,480
  10,257
  11,064
  11,901
  12,771
  13,674
Retained Cash Flow (-), $m
  -120
  -52
  -55
  -76
  -100
  -128
  -161
  -198
  -238
  -281
  -326
  -373
  -421
  -469
  -517
  -564
  -611
  -656
  -701
  -744
  -787
  -829
  -870
  -910
  -951
  -991
  -1,032
  -1,074
  -1,117
  -1,161
Prev. year cash balance distribution, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  11
  18
  28
  42
  61
  86
  118
  158
  208
  268
  338
  420
  513
  619
  736
  865
  1,007
  1,160
  1,324
  1,499
  1,686
  1,883
  2,090
  2,308
  2,536
  2,774
  3,022
  3,281
  3,550
  3,829
Cash available for distribution, $m
  -22
  73
  105
  156
  245
  358
  498
  667
  868
  1,101
  1,358
  1,660
  1,996
  2,367
  2,773
  3,211
  3,681
  4,184
  4,717
  5,280
  5,872
  6,494
  7,144
  7,822
  8,529
  9,265
  10,031
  10,827
  11,654
  12,513
Discount rate, %
  13.60
  14.28
  14.99
  15.74
  16.53
  17.36
  18.23
  19.14
  20.09
  21.10
  22.15
  23.26
  24.42
  25.64
  26.93
  28.27
  29.69
  31.17
  32.73
  34.37
  36.08
  37.89
  39.78
  41.77
  43.86
  46.05
  48.36
  50.78
  53.31
  55.98
PV of cash for distribution, $m
  -19
  56
  69
  87
  114
  137
  154
  164
  167
  162
  150
  135
  117
  97
  78
  60
  44
  32
  22
  14
  9
  6
  3
  2
  1
  0
  0
  0
  0
  0
Current shareholders' claim on cash, %
  8.1
  4.0
  3.3
  3.3
  3.3
  3.3
  3.3
  3.3
  3.3
  3.3
  3.3
  3.3
  3.3
  3.3
  3.3
  3.3
  3.3
  3.3
  3.3
  3.3
  3.3
  3.3
  3.3
  3.3
  3.3
  3.3
  3.3
  3.3
  3.3
  3.3

Aralez Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company's products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G. Its development products include YOSPRALA and Bilastine. Fibricor (fenofibric acid) is indicated as a complementary therapy along with diet for the treatment of hypertriglyceridemia, and as a complementary therapy along with diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG) and apolipoprotein B (Apo B). Fibricor is also used to increase high-density lipoprotein (HDL) cholesterol (HDL-C) in patients with hypercholesterolemia or mixed dyslipidemia. Cambia (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug (NSAID).

FINANCIAL RATIOS  of  Aralez Pharmaceuticals (ARLZ)

Valuation Ratios
P/E Ratio 0
Price to Sales 0
Price to Book 0
Price to Tangible Book
Price to Cash Flow 0
Price to Free Cash Flow 0
Growth Rates
Sales Growth Rate -100%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate NaN%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio NaN
Current Ratio NaN
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets 0%
Ret/ On Assets - 3 Yr. Avg. 0%
Return On Total Capital 0%
Ret/ On T. Cap. - 3 Yr. Avg. 0%
Return On Equity 0%
Return On Equity - 3 Yr. Avg. 0%
Asset Turnover 0
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin 0%
EBITDA Margin - 3 Yr. Avg. 0%
Operating Margin 0%
Oper. Margin - 3 Yr. Avg. 0%
Pre-Tax Margin 0%
Pre-Tax Margin - 3 Yr. Avg. 0%
Net Profit Margin 0%
Net Profit Margin - 3 Yr. Avg. 0%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

ARLZ stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the ARLZ stock intrinsic value calculation we used $106 million for the last fiscal year's total revenue generated by Aralez Pharmaceuticals. The default revenue input number comes from 2017 income statement of Aralez Pharmaceuticals. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our ARLZ stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 13.6%, whose default value for ARLZ is calculated based on our internal credit rating of Aralez Pharmaceuticals, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Aralez Pharmaceuticals.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of ARLZ stock the variable cost ratio is equal to 57.6%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $128 million in the base year in the intrinsic value calculation for ARLZ stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 9.8% for Aralez Pharmaceuticals.

Corporate tax rate of 27% is the nominal tax rate for Aralez Pharmaceuticals. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the ARLZ stock is equal to 10.7%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for ARLZ are equal to 388.8%.

Life of production assets of 10 years is the average useful life of capital assets used in Aralez Pharmaceuticals operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for ARLZ is equal to -16%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $15 million for Aralez Pharmaceuticals - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 66 million for Aralez Pharmaceuticals is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Aralez Pharmaceuticals at the current share price and the inputted number of shares is $0.0 billion.

RELATED COMPANIES Price Int.Val. Rating
AZN AstraZeneca AD 38.12 55.39  str.buy
HZNP Horizon Pharma 20.57 0.62  str.sell
ANIK Anika Therapeu 42.11 52.40  hold

COMPANY NEWS

▶ [$$] Drug Company Aralez Files for Bankruptcy, Plans to Sell Most Assets   [Aug-10-18 01:16PM  The Wall Street Journal]
▶ Aralez Pharmaceuticals: 1Q Earnings Snapshot   [May-08-18 07:26AM  Associated Press]
▶ Aralez Announces New Strategic Direction   [06:55AM  PR Newswire]
▶ ARLZ: Aralez Set for Strong Revenue Growth in 2018   [Mar-19-18 10:00AM  Zacks Small Cap Research]
▶ Why Aralez Pharmaceuticals Inc (TSE:ARZ) Could Be A Buy   [Feb-13-18 12:37PM  Simply Wall St.]
▶ Aralez Announces Departure of Chief Financial Officer   [Nov-30-17 05:00PM  PR Newswire]
▶ ARLZ: Increasing Revenue Projections for 2018   [Nov-13-17 06:00PM  Zacks Small Cap Research]
▶ Aralez Pharmaceuticals reports 3Q loss   [07:32AM  Associated Press]
▶ ARLZ: Looking to Capitalize on Successful Launch of Zontivity┬«   [Aug-10-17 03:00PM  Zacks Small Cap Research]
▶ Aralez Reports Second Quarter 2017 Financial Results   [Aug-09-17 07:00AM  PR Newswire]
▶ Aralez to present at the Jefferies Healthcare Conference   [May-23-17 07:00AM  PR Newswire]
▶ ARLZ: Zontivity to be Officially Launched in June 2017   [May-15-17 01:00PM  Zacks Small Cap Research]
▶ Aralez Pharmaceuticals reports 1Q loss   [May-09-17 08:51AM  Associated Press]
▶ ARLZ: 2016 Financial Results and Guidance for 2017   [01:00PM  Zacks Small Cap Research]
▶ Why Aralez Pharmaceuticals Inc. Got Slaughtered Today   [Mar-13-17 03:47PM  Motley Fool]
▶ Aralez Pharmaceuticals reports 4Q loss   [07:42AM  Associated Press]
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.